Market research
SAGE Sage Therapeutic
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 545M
- P/E ratio
- Not available
- Analyst target
- 8.5833
- Dividend yield
- Not available
- Beta
- 0.3
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US78667J1088
- Market cap
- 545M
- P/E ratio
- Not available
- Analyst target
- 8.5833
- Dividend yield
- Not available
- Beta
- 0.3
About
About Sage Therapeutic
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SAGE discussion.
5 years, 4 months ago
Sage Therapeutics, Inc is currently in a long term downtrend where the price is trading 27.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Sage Therapeutics, Inc's total revenue rose by 56491.1% to $1B since the same quarter in the previous year.
Its net income has increased by 678.0% to $975M since the same quarter in the previous year.
Finally, its free cash flow grew by 963.3% to $1B since the same quarter in the previous year.
Based on the above factors, Sage Therapeutics, Inc gets an overall score of 4/5.